Bristol-Myers Squibb Co (BMY) Shares Sold by WealthTrust Axiom LLC

WealthTrust Axiom LLC lowered its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 127,209 shares of the biopharmaceutical company’s stock after selling 1,700 shares during the quarter. Bristol-Myers Squibb comprises 3.1% of WealthTrust Axiom LLC’s portfolio, making the stock its 2nd largest holding. WealthTrust Axiom LLC’s holdings in Bristol-Myers Squibb were worth $8,108,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the business. Blue Chip Partners Inc. lifted its holdings in shares of Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 15 shares during the last quarter. Jackson Grant Investment Advisers Inc. lifted its holdings in shares of Bristol-Myers Squibb by 0.4% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 15 shares during the last quarter. Chilton Investment Co. LLC lifted its holdings in shares of Bristol-Myers Squibb by 0.5% during the second quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after buying an additional 26 shares during the last quarter. Keel Point LLC lifted its holdings in shares of Bristol-Myers Squibb by 0.6% during the second quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock worth $352,000 after buying an additional 39 shares during the last quarter. Finally, Hudock Capital Group LLC lifted its holdings in shares of Bristol-Myers Squibb by 0.4% during the second quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock worth $656,000 after buying an additional 49 shares during the last quarter. 69.75% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Co (BMY) traded up $0.73 during trading on Friday, reaching $64.25. The company’s stock had a trading volume of 6,426,406 shares, compared to its average volume of 6,290,000. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Co has a 1 year low of $47.12 and a 1 year high of $66.10. The firm has a market capitalization of $105,160.00, a price-to-earnings ratio of 25.30, a P/E/G ratio of 2.20 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same quarter in the prior year, the company earned $0.77 earnings per share. The business’s revenue was up 6.7% compared to the same quarter last year. sell-side analysts forecast that Bristol-Myers Squibb Co will post 2.99 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be paid a dividend of $0.40 per share. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.49%. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 62.99%.

A number of research analysts recently commented on BMY shares. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 target price for the company in a research note on Wednesday, November 1st. SunTrust Banks upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Citigroup set a $72.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Wednesday, October 25th. Vetr upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 target price for the company in a research note on Monday, October 9th. Finally, UBS Group restated a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $65.38.

In other news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the sale, the executive vice president now owns 9,251 shares in the company, valued at approximately $585,033.24. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Co (BMY) Shares Sold by WealthTrust Axiom LLC” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/28/bristol-myers-squibb-co-bmy-position-trimmed-by-wealthtrust-axiom-llc.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply